Systematic Review with Meta-Analysis: Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C Genotypes 5 and 6

Table 4

Efficacy of DAA regimens on HCV genotype 5 and 6 patients.

Regimen	Study	Duration (weeks)	Total patients	SVR12 rate (%)	Pooled SVR12 rate (95% CI)
GENOTYPE 5
SOF + PR	Lawitz et al. [29]	12	1	100	NA
SOF/VEL	Feld et al. [23]	12	35	97.1	NA
SOF/LDV	Abergel et al. [20]	12	41	95.1	NA
SOF/VEL/VOX	Jacobson et al. [26]	8	18	94.4	NA
GENOTYPE 6
SOF + RBV	Lai et al. [28]	12	3	100	NA
	Lai et al. [28]	16	4	100	NA
	Lai et al. [28]	24	4	100	NA
	Wei et al. [32]	24	4	100
SOF + PR	Wei et al. [32]	12	32	96.9	99.6% (92.2%, 100%)
	Lawitz et al. [29]	12	6	100
	Kowdley et al. [27]	24	5	100
SOF/VEL	Everson et al. [22]	12	5	100	NA
	Feld et al. [23]	12	41	100
	Jacobson et al. [26]	12	9	100
	Curry et al. [21]	24	1	100
SOF/VEL 25 mg	Everson et al. [22]	12	4	100	NA
SOF/LDV	Nguyen et al. [30]	8	20	95	NA
	Nguyen et al. [30]	12	40	95	99.2% (96.5%, 100%)
	Gane et al. [24]	12	25	96
	Thuy et al. [31]	12	86	100
	Thuy et al. [31]	24	20	100	NA
SOF/LDV + RBV	Thuy et al. [31]	12	39	100	NA
	Thuy et al. [31]	24	30	100	NA
SOF/VEL/VOX	Jacobson et al. [26]	8	30	100	NA
	Gane et al. [25]	8	1	100
	Gane et al. [25]	12	2	100	NA

SOF, sofosbuvir; VEL, velpatasvir; LDV, ledipasvir; VOX, voxilaprevir; PR, PegIFN + ribavirin; RBV, ribavirin; SVR12, sustained virological response rates at 12^th week after treatment; NA, nonapplicable. Standard dose of each drug was as follows: SOF, 400 mg per day; VEL, 100 mg per day; LDV, 90 mg per day; VOX, 100 mg per day; PegIFN 180 μg per week; RBV 1000–1200 mg per day. The confidence intervals were estimated with the exact method, as recommended by Nyaga et al. [19] who developed the statistical program used for pooling in this study. Standard dose of VEL is 100 mg per day. In this study (Everson 2005), a VEL dose of 25 mg per day was experimented.